---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016850"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:43:45.164532+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eledon Q2 net loss $9.2M; advances tegoprubart trials across kidney, IgAN, ALS

## Summary
- Net loss of $9.2M ($0.65 per share) vs $7.4M loss in Q2 2021.
- Cash at $70.5M; management expects to fund operations into 2024.
- FDA cleared IND for Phase 2 kidney transplant trial; first patient dosed in Phase 1b ex-US kidney study.
- Positive Phase 2a ALS topline: tegoprubart met safety endpoints; showed target engagement and biomarker reduction.
- Orphan Drug Designation granted for tegoprubart in islet cell transplantation; IgAN trial enrollment ongoing.

## SEC filing metadata
- accession: 0000950170-22-016850
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017022016850/0000950170-22-016850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017022016850/eldn-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016850
- JSON: https://secwatch.observer/filing/0000950170-22-016850.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016850.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.